10X Genomics Inc Total Assets
10X Genomics Inc total assets. Based on the latest financial reports, 10X Genomics Inc (TXG) holds total assets worth $1.03 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TXG stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of 10X Genomics Inc (2017–2025)
Total assets of 10X Genomics Inc from 2017 to 2025. This chart illustrates how 10X Genomics Inc's total assets have evolved over time, based on quarterly financial data. See TXG stock price for real-time trading data and today's change.
10X Genomics Inc - Asset Composition Analysis
10X Genomics Inc Total Assets Breakdown (December 2025)
10X Genomics Inc total assets breakdown as of December 2025. 10X Genomics Inc's total assets of $1.03 Billion consist of 65.7% current assets and 34.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.5% |
| Accounts Receivable | $82.49 Million | 7.9% |
| Inventory | $56.34 Million | 5.4% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $62.33 Million | 6.0% |
| Goodwill | $4.51 Million | 0.4% |
Asset Composition Trend (2017–2025)
This chart illustrates how 10X Genomics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of 10X Genomics Inc to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 10X Genomics Inc's current assets represent 65.7% of total assets in 2025, a decrease from 90.1% in 2017.
- Cash Position: Cash and equivalents constituted 45.5% of total assets in 2025, down from 63.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
10X Genomics Inc Competitors by Total Assets
Key competitors of 10X Genomics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
10X Genomics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.69 | 5.84 | 7.41 |
| Quick Ratio | 5.25 | 5.23 | 6.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $556.16 Million | $543.44 Million | $643.73 Million |
10X Genomics Inc - Advanced Valuation Insights
This section examines the relationship between 10X Genomics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.35 |
| Latest Market Cap to Assets Ratio | 8.09 |
| Asset Growth Rate (YoY) | 13.4% |
| Total Assets | $1.04 Billion |
| Market Capitalization | $8.43 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values 10X Genomics Inc's assets at a significant premium (8.09x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: 10X Genomics Inc's assets grew by 13.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for 10X Genomics Inc (2017–2025)
The table below shows the annual total assets of 10X Genomics Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.04 Billion | +13.36% |
| 2024-12-31 | $918.64 Million | -4.82% |
| 2023-12-31 | $965.14 Million | -6.20% |
| 2022-12-31 | $1.03 Billion | +1.00% |
| 2021-12-31 | $1.02 Billion | +9.63% |
| 2020-12-31 | $929.34 Million | +53.38% |
| 2019-12-31 | $605.92 Million | +387.43% |
| 2018-12-31 | $124.31 Million | +64.41% |
| 2017-12-31 | $75.61 Million | -- |
About 10X Genomics Inc
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related… Read more